Unnamed: 0,title,date,stock,sentiment
46692.0,AGTC Announces Publication Of Preclinical Data That Provides Foundational Scientific Evidence For Its Ongoing Clinical Program In Patients With X-Linked Retinitis Pigmentosa (XLRP),2020-05-20 07:10:00-04:00,AGTC,neutral
46693.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,AGTC,neutral
46694.0,Applied Genetic Tech Q3 EPS $(0.500) Beats $(0.550) Estimate,2020-05-13 07:09:00-04:00,AGTC,neutral
46695.0,Otonomy And AGTC To Present Preclinical Results Supporting Selection Of Product Candidate For GJB2 Gene Therapy Hearing Loss Program,2020-05-12 08:06:00-04:00,AGTC,positive
46696.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,AGTC,neutral
46697.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,AGTC,positive
46698.0,AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsia,2020-03-16 07:12:00-04:00,AGTC,neutral
46699.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-02-19 08:10:00-05:00,AGTC,neutral
46700.0,AGTC Announces Completion Of Enrollment In The Two Highest Dose Groups Of Its Ongoing Phase 1/2 Clinical Trial In Patients With X-Linked Retinitis Pigmentosa,2020-02-19 07:15:00-05:00,AGTC,neutral
46701.0,95 Biggest Movers From Friday,2020-02-10 05:20:00-05:00,AGTC,neutral
46702.0,Applied Genetic Technologies shares are trading lower after the company priced its common stock offering of 6.5 million shares at $5 per share.,2020-02-07 11:42:00-05:00,AGTC,positive
46703.0,16 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-02-07 07:39:00-05:00,AGTC,neutral
46704.0,10 Biotechnology Stocks Moving In Friday's Pre-Market Session,2020-02-07 07:35:00-05:00,AGTC,neutral
46705.0,46 Stocks Moving in Friday's Pre-Market Session,2020-02-07 07:25:00-05:00,AGTC,neutral
46706.0,AGTC Prices 6.5M Share Public Offering of Common Stock @$5.00/Share,2020-02-07 05:30:00-05:00,AGTC,positive
46707.0,100 Biggest Movers From Yesterday,2020-02-07 04:30:00-05:00,AGTC,neutral
46708.0,74 Stocks Moving In Thursday's Mid-Day Session,2020-02-06 12:38:00-05:00,AGTC,neutral
46709.0,Applied Genetic Technologies shares are trading lower after the company announced a proposed public offering of common stock of 6 million shares.,2020-02-06 11:37:00-05:00,AGTC,positive
46710.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,AGTC,negative
46711.0,44 Stocks Moving in Thursday's Pre-Market Session,2020-02-06 07:26:00-05:00,AGTC,neutral
46712.0,"12 Stocks To Watch For February 6, 2020",2020-02-06 04:51:00-05:00,AGTC,neutral
46713.0,19 Stocks Moving In Wednesday's After Hours,2020-02-05 17:31:00-05:00,AGTC,neutral
46714.0,Applied Genetic Technologies shares are trading lower after the company announced a proposed public offering of common stock of 6 million shares.,2020-02-05 16:53:00-05:00,AGTC,positive
46715.0,AGTC Announces Proposed Public Offering of Common Stock Of 6 Million Shares,2020-02-05 16:48:00-05:00,AGTC,positive
46716.0,"Exclusive: Applied Genetic's CEO Talks Partnerships, Politics, Pipeline",2020-01-31 08:20:00-05:00,AGTC,positive
46717.0,70 Biggest Movers From Yesterday,2020-01-31 05:24:00-05:00,AGTC,neutral
46718.0,50 Stocks Moving In Thursday's Mid-Day Session,2020-01-30 13:37:00-05:00,AGTC,neutral
46719.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,AGTC,positive
46720.0,Applied Genetic Technologies Files For $35M Common Stock Offering,2020-01-29 17:32:00-05:00,AGTC,neutral
46721.0,"Applied Genetic Technologies CEO Sue Washer Notes To Benzinga Co. Signaled, At R&D Day Tues., Mgmt. Is Interested In Exploring Partnerships For Co.'s Earlier Stages Of Development Or For Commercialization/Late-Stage Regulatory Development In Non-US Market",2020-01-28 13:44:00-05:00,AGTC,positive
46722.0,"Benzinga's Top Upgrades, Downgrades For January 28, 2020",2020-01-28 09:43:00-05:00,AGTC,positive
46723.0,"Otonomy Offers Preclinical Results For GJB2 Gene Therapy Collaboration, Cisplatin Otoprotection Program",2020-01-28 07:33:00-05:00,AGTC,neutral
46724.0,"Roth Capital Initiates Coverage On Applied Genetic Tech with Buy Rating, Announces $25 Price Target",2020-01-28 06:27:00-05:00,AGTC,neutral
46725.0,23 Biotechnology Stocks Moving In Monday's After-Market Session,2020-01-27 23:45:00-05:00,AGTC,neutral
46726.0,36 Healthcare Stocks Moving In Monday's After-Market Session,2020-01-27 23:41:00-05:00,AGTC,neutral
46727.0,70 Biggest Movers From Friday,2020-01-27 04:02:00-05:00,AGTC,neutral
46728.0,44 Stocks Moving In Friday's Mid-Day Session,2020-01-24 12:08:00-05:00,AGTC,neutral
46729.0,15 Biotechnology Stocks Moving In Thursday's After-Market Session,2020-01-23 23:28:00-05:00,AGTC,neutral
46730.0,20 Healthcare Stocks Moving In Thursday's After-Market Session,2020-01-23 23:13:00-05:00,AGTC,neutral
46731.0,Mid-Afternoon Market Update: Crude Oil Down 2.5%; Trans World Entertainment Shares Spike Higher,2020-01-23 14:34:00-05:00,AGTC,positive
46732.0,36 Stocks Moving In Thursday's Mid-Day Session,2020-01-23 14:05:00-05:00,AGTC,neutral
46733.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,AGTC,neutral
46734.0,Mid-Day Market Update: Markets Down; Procter & Gamble  Reports Mixed Q2 Results,2020-01-23 11:48:00-05:00,AGTC,neutral
46735.0,Applied Genetic Slumps Despite Encouraging Data For Gene Therapy To Treat Rare Inherited Visual Disorder,2020-01-23 10:22:00-05:00,AGTC,negative
46736.0,Applied Genetic Technologies shares are trading lower after the company reported interim six-month data from the dose-escalation cohorts of its ongoing Phase 1/2 clinical programs. The company plans to report additional data in Q2 2020.,2020-01-23 09:12:00-05:00,AGTC,neutral
46737.0,15 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-01-23 07:36:00-05:00,AGTC,neutral
46738.0,12 Biotechnology Stocks Moving In Thursday's Pre-Market Session,2020-01-23 07:35:00-05:00,AGTC,neutral
46739.0,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",2020-01-23 07:24:00-05:00,AGTC,positive
46740.0,Applied Genetic Technologies Reports Interim 6-Month Data From Dose-Escalation Cohorts Of Ongoing Phase 1/2 Trials In Achromatopsia,2020-01-23 07:11:00-05:00,AGTC,neutral
46741.0,70 Biggest Movers From Yesterday,2020-01-23 05:52:00-05:00,AGTC,neutral
46742.0,"Applied Genetic Technologies shares are trading higher, not currently seeing any company-specific news.",2020-01-22 14:08:00-05:00,AGTC,positive
46743.0,80 Biggest Movers From Yesterday,2020-01-15 04:48:00-05:00,AGTC,neutral
46744.0,55 Biggest Movers From Friday,2020-01-13 05:17:00-05:00,AGTC,neutral
46745.0,40 Stocks Moving In Friday's Mid-Day Session,2020-01-10 12:29:00-05:00,AGTC,neutral
46746.0,21 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-01-10 07:38:00-05:00,AGTC,neutral
46747.0,33 Stocks Moving in Friday's Pre-Market Session,2020-01-10 07:26:00-05:00,AGTC,neutral
46748.0,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx",2020-01-10 07:13:00-05:00,AGTC,positive
46749.0,64 Biggest Movers From Yesterday,2020-01-10 04:58:00-05:00,AGTC,neutral
46750.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-09 15:15:00-05:00,AGTC,neutral
46751.0,Mid-Afternoon Market Update: Bed Bath & Beyond Tumbles Following Q3 Miss; Applied Genetic Technologies Shares Jump,2020-01-09 15:11:00-05:00,AGTC,positive
46752.0,"Hearing BMO Raised Applied Genetic Technologies Price Target From $9 To $16/Share, Saying Data Is A 'Clear Win'; Unconfirmed",2020-01-09 15:00:00-05:00,AGTC,positive
46753.0,32 Stocks Moving In Thursday's Mid-Day Session,2020-01-09 12:08:00-05:00,AGTC,neutral
46754.0,Applied Genetic Shares Rip Higher After Eye Disorder Gene Therapy Aces Midstage Trial,2020-01-09 10:02:00-05:00,AGTC,negative
46755.0,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results",2020-01-09 08:39:00-05:00,AGTC,positive
46756.0,Applied Genetic Technologies shares are trading higher after the company reported the results from its ongoing Phase 1/2 clinical program in X-linked retinitis pigmentosa demonstrated durable improvement in visual function six months after dosing.,2020-01-09 07:27:00-05:00,AGTC,positive
46757.0,Applied Genetic Technologies Reports 6-Month Data From Ongoing Phase 1/2 Trial In X-Linked Retinitis Rigmentosa,2020-01-09 07:08:00-05:00,AGTC,neutral
46758.0,"The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping",2019-12-27 07:59:00-05:00,AGTC,neutral
46759.0,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares",2019-12-26 07:55:00-05:00,AGTC,negative
46760.0,51 Biggest Movers From Tuesday,2019-12-26 05:14:00-05:00,AGTC,neutral
46761.0,33 Stocks Moving In Tuesday's Mid-Day Session,2019-12-24 11:34:00-05:00,AGTC,neutral
46762.0,60 Biggest Movers From Friday,2019-12-23 05:37:00-05:00,AGTC,neutral
46763.0,40 Stocks Moving In Friday's Mid-Day Session,2019-12-20 12:07:00-05:00,AGTC,neutral
46764.0,Mid-Morning Market Update: Markets Open Higher; BlackBerry Earnings Beat Views,2019-12-20 10:17:00-05:00,AGTC,neutral
46765.0,"The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial",2019-12-03 07:59:00-05:00,AGTC,neutral
46766.0,"AGTC Announces Departure Of Chief Medical Officer; Says Departure Not Related To Knowledge Of Pending Trial Results, Says Remains On Track To Announce XLRP and ACHM Data in January 2020",2019-12-02 16:37:00-05:00,AGTC,neutral
46767.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,AGTC,neutral
46768.0,"The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict",2019-11-10 16:08:00-05:00,AGTC,positive
46769.0,38 Biggest Movers From Yesterday,2019-10-22 06:42:00-04:00,AGTC,neutral
46770.0,33 Stocks Moving In Monday's Mid-Day Session,2019-10-21 12:32:00-04:00,AGTC,neutral
46771.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-02 08:54:00-04:00,AGTC,neutral
46772.0,AGTC And Otonomy Announce Strategic Collaboration To Develop And Commercialize Gene Therapy For Congenital Hearing Loss,2019-10-01 07:32:00-04:00,AGTC,negative
46773.0,Applied Genetic Notches Sell-Side Upgrade After Releasing Interim Study Data,2019-09-30 12:03:00-04:00,AGTC,neutral
46774.0,34 Stocks Moving In Friday's Mid-Day Session,2019-09-27 12:11:00-04:00,AGTC,neutral
46775.0,"Benzinga's Top Upgrades, Downgrades For September 27, 2019",2019-09-27 09:39:00-04:00,AGTC,positive
46776.0,21 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-27 08:45:00-04:00,AGTC,neutral
46777.0,25 Stocks Moving in Friday's Pre-Market Session,2019-09-27 08:27:00-04:00,AGTC,neutral
46778.0,"The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave",2019-09-27 07:56:00-04:00,AGTC,positive
46779.0,"Wedbush Maintains Outperform on Applied Genetic Tech, Raises Price Target to $12",2019-09-27 07:47:00-04:00,AGTC,neutral
46780.0,"BMO Capital Upgrades Applied Genetic Tech to Outperform, Raises Price Target to $9",2019-09-27 06:11:00-04:00,AGTC,neutral
46781.0,"Applied Genetic Tech Sees Total Cash, Cash Equivalents, Investments As Of Jun. 30, 2020 $30M-$40M",2019-09-26 16:04:00-04:00,AGTC,neutral
46782.0,Applied Genetic Tech Q4 EPS $(0.58) Misses $(0.54) Estimate,2019-09-26 16:03:00-04:00,AGTC,negative
46783.0,"The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J",2019-09-26 07:54:00-04:00,AGTC,positive
46784.0,"Earnings Scheduled For September 26, 2019",2019-09-26 04:06:00-04:00,AGTC,neutral
46785.0,64 Biggest Movers From Friday,2019-09-09 05:43:00-04:00,AGTC,neutral
46786.0,46 Stocks Moving In Friday's Mid-Day Session,2019-09-06 12:09:00-04:00,AGTC,neutral
46787.0,Applied Genetic Technologies shares are trading higher after Janney Capital initiated coverage on the stock with a Buy rating.,2019-09-06 11:34:00-04:00,AGTC,positive
46788.0,"Benzinga's Top Upgrades, Downgrades For September 6, 2019",2019-09-06 09:37:00-04:00,AGTC,positive
46789.0,Janney Capital Initiates Coverage On Applied Genetic Tech with Buy Rating,2019-09-06 07:38:00-04:00,AGTC,neutral
46790.0,"Chardan Capital Upgrades Applied Genetic Tech to Buy, Announces $7.5 Price Target",2019-09-03 09:34:00-04:00,AGTC,neutral
46791.0,70 Biggest Movers From Yesterday,2019-08-30 04:05:00-04:00,AGTC,neutral
46792.0,75 Biggest Movers From Yesterday,2019-08-16 05:16:00-04:00,AGTC,neutral
46793.0,AGTC Completes Enrollment Of Third Group In The Dose Escalation Portion Of Achromatopsia CNGA3 Phase 1/2 Clinical Study,2019-07-23 07:12:00-04:00,AGTC,neutral
46794.0,"Applied Genetic Tech Q3 EPS $0.63 Beats $(0.58) Estimate, Sales $21.318M Beat $2.65M Estimate",2019-05-07 07:28:00-04:00,AGTC,neutral
46795.0,Applied Genetic Technologies Reports Achieved Enrollment Milestones In 2 Phase 1/2 Trials,2019-04-08 07:11:00-04:00,AGTC,neutral
46796.0,Analysts Laud Biogen's M&A Strategy Following Deal to Buy Gene Therapy Company Nightstar,2019-03-05 13:01:00-05:00,AGTC,neutral
46797.0,"Applied Genetic Tech Earlier Reported Q2 EPS $(0.23) Beats $(0.68) Estimate, Sales $5.934M Beat $2.64M Estimate",2019-02-07 08:42:00-05:00,AGTC,neutral
46798.0,When Larger Firms Walk Away From Partnerships With Smaller Ones: How Bad Is The Damage?,2018-12-21 13:38:00-05:00,AGTC,negative
46799.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,AGTC,neutral
46800.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,AGTC,negative
46801.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,AGTC,positive
46802.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,AGTC,negative
46803.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,AGTC,positive
46804.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,AGTC,positive
46805.0,"Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018",2018-12-17 11:48:00-05:00,AGTC,negative
46806.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018",2018-12-14 11:03:00-05:00,AGTC,negative
46807.0,51 Biggest Movers From Yesterday,2018-12-14 05:00:00-05:00,AGTC,neutral
46808.0,Mid-Afternoon Market Update: Crude Oil Up 2.8%; Tailored Brands Shares Plummet,2018-12-13 15:12:00-05:00,AGTC,negative
46809.0,Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?,2018-12-13 13:40:00-05:00,AGTC,neutral
46810.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-12-13 13:11:00-05:00,AGTC,neutral
46811.0,Mid-Day Market Update: Fred's Drops After Q3 Results; Adial Pharmaceuticals Shares Surge,2018-12-13 11:54:00-05:00,AGTC,positive
46812.0,Mid-Morning Market Update: Markets Open Higher; Ciena Tops Q4 Expectations,2018-12-13 10:16:00-05:00,AGTC,positive
46813.0,Applied Genetic Technologies shares are down on continued weakness after the company reported its gene delivery platform did not show signs of clinical activity and Biogen terminated their collaboration agreement; BMO analysts downgraded the stock.,2018-12-13 09:15:00-05:00,AGTC,positive
46814.0,"BMO Capital Downgrades Applied Genetic Tech to Market Perform, Lowers Target to $5",2018-12-13 08:41:00-05:00,AGTC,negative
46815.0,Applied Genetic Technologies shares are trading lower after the company reported its gene delivery platform did not show signs of clinical activity and Biogen terminated their collaboration agreement.,2018-12-13 08:38:00-05:00,AGTC,positive
46816.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-12-13 08:02:00-05:00,AGTC,neutral
46817.0,"The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen",2018-12-13 07:56:00-05:00,AGTC,positive
46818.0,5 Stocks Moving In Wednesday's After-Hours Session,2018-12-12 17:06:00-05:00,AGTC,neutral
46819.0,Applied Genetic Technologies Corp shares fall 32.7% after the company reported its gene delivery platform did not show signs of clinical activity and Biogen terminated their collaboration agreement.,2018-12-12 16:38:00-05:00,AGTC,positive
46820.0,"Applied Genetic Technologies Shares Resume Trade, Down 35%",2018-12-12 16:33:00-05:00,AGTC,positive
46821.0,"Applied Genetic Technologies Says Is On Track To Advance Phase 1/2 Studies In Achromatopsia, X-Linked Retinitis Pigmentosa",2018-12-12 16:09:00-05:00,AGTC,neutral
46822.0,Applied Genetic Technologies Shares To Resume Trade At 4:30 p.m. EST,2018-12-12 16:07:00-05:00,AGTC,positive
46823.0,UPDATE: Applied Genetic Technologies Reports Will 'regain rights to 5 clinical and preclinical development programs; Biogen terminates collaboration agreement',2018-12-12 16:02:00-05:00,AGTC,positive
46824.0,Applied Genetic Technologies Reports 'Results from XLRS study support general safety and tolerability of AGTC's gene delivery platform but did not demonstrate signs of clinical activity at interim six-month time point',2018-12-12 16:02:00-05:00,AGTC,positive
46825.0,Applied Genetic Tech Shares Halted News Pending,2018-12-12 16:01:00-05:00,AGTC,positive
46826.0,"Applied Genetic Q1 EPS $0.07 Beats $(0.39) Estimate, Sales $14.034M Beat $6.93M Estimate",2018-11-08 08:59:00-05:00,AGTC,neutral
46827.0,"The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results",2018-09-28 08:10:00-04:00,AGTC,positive
46828.0,51 Biggest Movers From Yesterday,2018-09-28 05:15:00-04:00,AGTC,neutral
46829.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-09-27 12:37:00-04:00,AGTC,neutral
46830.0,30 Stocks Moving In Thursday's Pre-Market Session,2018-09-27 08:10:00-04:00,AGTC,neutral
46831.0,"Stocks Which Set New 52-Week High Yesterday, September 25th",2018-09-26 11:53:00-04:00,AGTC,neutral
46832.0,"The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial",2018-09-26 08:25:00-04:00,AGTC,positive
46833.0,51 Biggest Movers From Yesterday,2018-09-26 05:17:00-04:00,AGTC,neutral
46834.0,41 Stocks Moving In Tuesday's Mid-Day Session,2018-09-25 13:06:00-04:00,AGTC,neutral
46835.0,51 Biggest Movers From Yesterday,2018-09-25 04:53:00-04:00,AGTC,neutral
46836.0,Mid-Afternoon Market Update: Crude Oil Up 2%; Astrotech Shares Plunge,2018-09-24 14:31:00-04:00,AGTC,negative
46837.0,42 Stocks Moving In Monday's Mid-Day Session,2018-09-24 12:39:00-04:00,AGTC,neutral
46838.0,Wells Fargo Bullish On Applied Genetic Technologies Ahead Of Program Update,2018-09-24 09:29:00-04:00,AGTC,positive
46839.0,"Benzinga's Top Upgrades, Downgrades For September 24, 2018",2018-09-24 09:17:00-04:00,AGTC,positive
46840.0,Applied Genetic Technologies shares are up 21.6% after Wells Fargo analysts upgraded the stock from Market Perform to Outperform and raised the price target from $20 to $6.,2018-09-24 08:55:00-04:00,AGTC,positive
46841.0,24 Stocks Moving In Monday's Pre-Market Session,2018-09-24 08:27:00-04:00,AGTC,neutral
46842.0,"Wells Fargo Upgrades Applied Genetic Tech to Outperform, Raises Price Target to $6",2018-09-24 07:13:00-04:00,AGTC,positive
46843.0,48 Biggest Movers From Yesterday,2018-09-12 05:20:00-04:00,AGTC,neutral
46844.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-09-11 12:31:00-04:00,AGTC,neutral
46845.0,10 Biggest Price Target Changes For Tuesday,2018-09-11 09:49:00-04:00,AGTC,neutral
46846.0,"Benzinga's Top Upgrades, Downgrades For September 11, 2018",2018-09-11 09:13:00-04:00,AGTC,positive
46847.0,"Chardan Capital Downgrades Applied Genetic Tech to Neutral, Lowers Price Target to $5",2018-09-11 06:22:00-04:00,AGTC,negative
46848.0,"Applied Genetic Tech Q4 EPS $(0.37) Misses $(0.17) Estimate, Sales $5.416M Miss $8.46M Estimate",2018-09-10 16:04:00-04:00,AGTC,negative
46849.0,Earnings Outlook for Applied Genetic Tech,2018-09-10 08:19:00-04:00,AGTC,neutral
46850.0,"Earnings Scheduled For September 10, 2018",2018-09-10 04:23:00-04:00,AGTC,neutral
46851.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs",2018-09-09 16:46:00-04:00,AGTC,neutral
46852.0,38 Biggest Movers From Yesterday,2018-07-24 04:06:00-04:00,AGTC,neutral
46853.0,34 Stocks Moving In Monday's Mid-Day Session,2018-07-23 12:42:00-04:00,AGTC,neutral
46854.0,AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns $10M Enrollment Milestone,2018-07-23 07:01:00-04:00,AGTC,neutral
46855.0,32 Stocks Moving In Monday's Mid-Day Session,2018-06-11 12:25:00-04:00,AGTC,neutral
46856.0,Applied Genetic Technologies S-3 Filling Shows Registration For $125M Mixed Securities Shelf Offering,2018-05-30 16:46:00-04:00,AGTC,positive
46857.0,45 Biggest Movers From Yesterday,2018-05-25 04:37:00-04:00,AGTC,neutral
46858.0,"Applied Genetic Tech Q3 EPS $(0.45) Misses $(0.41) Estimate, Sales $3.6M Miss $5.57M Estimate",2018-05-08 17:00:00-04:00,AGTC,negative
46859.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,AGTC,neutral
46860.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,AGTC,neutral
46861.0,AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa,2018-04-18 07:04:00-04:00,AGTC,neutral
46862.0,40 Biggest Movers From Friday,2018-04-16 05:19:00-04:00,AGTC,neutral
46863.0,30 Stocks Moving In Friday's Mid-Day Session,2018-04-13 12:17:00-04:00,AGTC,neutral
46864.0,41 Biggest Movers From Yesterday,2018-04-13 05:04:00-04:00,AGTC,neutral
46865.0,"Applied Genetic Technologies Sees Total Cash, Cash Equivalents, Investments As Of Jun. 30, 2018 $90M-$100M",2018-02-09 07:04:00-05:00,AGTC,neutral
46866.0,"Applied Genetic Technologies Reports Q4 Net Loss $5.2M vs $1.8M In Same Qtr. Last Year, Sales $4.9M vs $10.9M YoY",2018-02-09 07:03:00-05:00,AGTC,negative
46867.0,"Applied Genetic Technologies Reports Q3 EPS $(0.08) vs $(0.09) Est., Sales $10.315M vs $8.44M Est.",2017-11-07 17:39:00-05:00,AGTC,neutral
46868.0,Mid-Afternoon Market Update: Crude Oil Up Over 2%; Ballard Power Shares Spike Higher,2017-09-13 14:36:00-04:00,AGTC,negative
46869.0,12 Biggest Mid-Day Losers For Wednesday,2017-09-13 12:37:00-04:00,AGTC,negative
46870.0,Mid-Day Market Update: Applied Genetic Technologies Drops After Q4 Results; Inventure Foods Shares Surge,2017-09-13 12:00:00-04:00,AGTC,positive
46871.0,Mid-Morning Market Update: Markets Mostly Flat; Cracker Barrel Earnings Top Estimates,2017-09-13 10:15:00-04:00,AGTC,positive
46872.0,"AGTC Q4 EPS $(0.18) vs $0.06 Est., Sales $8.35M vs $11.92M Est.",2017-09-13 07:01:00-04:00,AGTC,neutral
46873.0,"Earnings Scheduled For September 13, 2017",2017-09-13 04:30:00-04:00,AGTC,neutral
46874.0,Applied Genetic Technologies Names Matthew Feinsod Interim CMO,2017-09-05 18:01:00-04:00,AGTC,neutral
46875.0,Applied Genetic Technologies Reports Filing Of Investigational NDA For Treatment Of X-Linked Retinitis Pigmentosa Caused By Mutations In RPGR Gene,2017-08-10 07:15:00-04:00,AGTC,neutral
46876.0,AGTC Reports U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa,2017-08-03 17:40:00-04:00,AGTC,positive
46877.0,20 Stocks Moving In Friday's Pre-Market Session,2017-06-23 08:19:00-04:00,AGTC,neutral
46878.0,Applied Genetic Technologies Reports Safety Data For X-Linked Retinoschisis Phase 1/2 Study,2017-06-08 16:00:00-04:00,AGTC,positive
46879.0,"Applied Genetic Technologies Reports Q1 EPS $(0.05) vs $(0.01) Est., Sales $8.388M vs $10.5M Est.",2017-05-10 16:13:00-04:00,AGTC,neutral
46880.0,UPDATE: Applied Genetic Technologies Says 'Results expected to enhance development of AGTC's XLRS gene therapy candidate; Phase 1/2 clinical trial currently enrolling patients at multiple locations across the US',2017-05-09 07:13:00-04:00,AGTC,neutral
46881.0,"Applied Genetic Technologies Reports Co., Casey Eye Institute, Retina Foundation, Kellogg Eye Center Showed Results from Study of Natural History of XLRS, Impact of CAIs on Disease Progression",2017-05-09 07:13:00-04:00,AGTC,positive
46882.0,"Benzinga's Top Upgrades, Downgrades For March 15, 2017",2017-03-15 09:40:00-04:00,AGTC,positive
46883.0,"Rodman & Renshaw Initiates Coverage On Applied Genetic Tech With Buy, Announces $16 Price Target",2017-03-15 07:04:00-04:00,AGTC,neutral
46884.0,"AGTC Reports Quarter Ended EPS $0.11 vs. Prior Year Quarter $0.17, Rev. $10.9M vs. Prior Year Quarter $12.18M",2017-02-08 16:14:00-05:00,AGTC,neutral
46885.0,Stifel Healthcare Conference Today,2016-11-15 10:53:00-05:00,AGTC,neutral
46886.0,15 Biggest Mid-Day Gainers For Wednesday,2016-11-09 12:33:00-05:00,AGTC,neutral
46887.0,8 Biggest Price Target Changes For Wednesday,2016-11-09 09:37:00-05:00,AGTC,neutral
46888.0,Benzinga's Top Upgrades,2016-11-09 08:55:00-05:00,AGTC,positive
46889.0,"Roth Capital Upgrades Applied Genetic Technologies Corporation - Common Stock to Buy, Raises to $15.00",2016-11-09 08:37:00-05:00,AGTC,neutral
46890.0,"Applied Genetic Technologies Reports Q3 EPS $0.20 vs $(0.53) in Same Qtr. Last Year, Sales $11.806M vs $10.2M Est.",2016-11-08 16:11:00-05:00,AGTC,neutral
46891.0,Janney Capital Upgrades Applied Genetic Tech to Neutral,2016-09-26 08:22:00-04:00,AGTC,neutral
46892.0,Mid-Afternoon Market Update: Crude Oil Down 3%; Applied Genetic Technologies Shares Slide,2016-09-13 14:43:00-04:00,AGTC,negative
46893.0,12 Biggest Mid-Day Losers For Tuesday,2016-09-13 13:53:00-04:00,AGTC,negative
46894.0,Mid-Day Market Update: Dow Tumbles 250 Points; Liberty Media Shares Spike Higher,2016-09-13 12:17:00-04:00,AGTC,positive
46895.0,Stocks Hitting 52-Week Lows,2016-09-13 10:28:00-04:00,AGTC,negative
46896.0,Mid-Morning Market Update: Markets Open Lower; Renesas Electronics To Acquire Intersil For $22.50/Share,2016-09-13 10:02:00-04:00,AGTC,negative
46897.0,Benzinga's Top Downgrades,2016-09-13 09:11:00-04:00,AGTC,positive
46898.0,The Market In 5 Minutes: The Fed And IEA Confuse The Market,2016-09-13 08:51:00-04:00,AGTC,negative
46899.0,Roth Capital Downgrades Applied Genetic Tech to Neutral,2016-09-13 08:44:00-04:00,AGTC,neutral
46900.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-09-13 08:21:00-04:00,AGTC,neutral
46901.0,Cantor Fitzgerald Downgrades Applied Genetic Tech to Hold,2016-09-13 07:18:00-04:00,AGTC,neutral
46902.0,Janney Capital Downgrades Applied Genetic Tech to Sell,2016-09-13 07:18:00-04:00,AGTC,neutral
46903.0,Wells Fargo Downgrades Applied Genetic Tech to Market Perform,2016-09-13 07:18:00-04:00,AGTC,positive
46904.0,"Applied Genetic Technologies Reports Q4 EPS $0.15 vs $0.07 Est., Sales $12.1M vs $13M Est.",2016-09-12 16:24:00-04:00,AGTC,neutral
46905.0,"Earnings Scheduled For September 12, 2016",2016-09-12 04:01:00-04:00,AGTC,neutral
46906.0,Applied Genetic Technologies Reports Orphan Medicinal Product Designation in EU for Gene Therapy to Treat X-Linked Retinitis Pigmentosa,2016-06-07 07:07:00-04:00,AGTC,positive
46907.0,"Applied Genetic Technologies Reports Q1 EPS $0.11 Vs Est $0.05, Sales $11.997M Vs Est $12.98M",2016-05-09 17:31:00-04:00,AGTC,neutral
46908.0,Investigational Gene-Based Therapy Developed By Applied Genetic Technologies for Alpha-1 Antitrypsin (AAT) Deficiency Demonstrates Durable Response at Five Years,2016-05-05 07:35:00-04:00,AGTC,neutral
46909.0,Applied Genetic Technologies Reports Novel Investigational Gene-Based Therapy for X-Linked Retinitis Pigmentosa Demonstrates Functional Rescue of Photoreceptor Structure and Function in Canine Model,2016-05-02 07:19:00-04:00,AGTC,positive
46910.0,"Applied Genetic Technologies Offers Data Evaluating Novel AAV-Based Gene Therapy as Potential Treatment for LCA, SECORD",2016-04-22 07:05:00-04:00,AGTC,positive
46911.0,"Applied Genetic Technologies Reports Publication of Safety, Biodistribution Data Show Support for Future Clinical Studies of Novel Gene Therapy for Treating Achromatopsia",2016-04-20 07:02:00-04:00,AGTC,positive
46912.0,Benzinga's Top Initiations,2016-03-18 09:12:00-04:00,AGTC,positive
46913.0,Janney Capital Initiates Coverage on Applied Genetic Tech at Buy,2016-03-18 07:59:00-04:00,AGTC,neutral
46914.0,"AGTC Reports Q2 EPS $0.17 vs $(0.28) in Same Qtr. Last Year, Sales $12.189M vs $8.8M Est.",2016-02-08 16:03:00-05:00,AGTC,neutral
46915.0,AGTC Reports Data Regarding Novel AAV Gene Therapy As Potential Treatment For AAT Deficiency,2016-01-20 07:03:00-05:00,AGTC,positive
46916.0,AGTC Reports Preclinical Data Evaluating Cone-Specific Promoters for Use in Gene Therapy of Achromatopsia and Other Retinal Diseases,2016-01-07 07:01:00-05:00,AGTC,neutral
46917.0,"AGTC, Synpromics Report R&D Partnership To Create Synthetic Promoters For Enhanced Gene Therapy Candidates, AGTC To Pay Synpromics $1.5M Upfront",2015-12-09 07:13:00-05:00,AGTC,positive
46918.0,Wells Fargo Initiates Coverage on Applied Genetic Tech at Outperform,2015-12-04 07:56:00-05:00,AGTC,positive
46919.0,15 Biotechs Making Announcements At The 2015 Piper Jaffray Healthcare Conference,2015-12-01 16:45:00-05:00,AGTC,neutral
46920.0,AGTC Reports U.S. FDA Orphan Drug Designation for Gene Therapy to Treat Achromatopsia,2015-11-23 07:02:00-05:00,AGTC,positive
46921.0,AGTC Files Investigational New Drug Application for the Treatment of Achromatopsia Caused by Mutations in the CNGB3 Gene,2015-11-02 07:05:00-05:00,AGTC,neutral
46922.0,Applied Genetic Technologies Announces Orphan Drug Designation in EU for Gene Therapy to Treat Achromatopsia,2015-10-22 07:33:00-04:00,AGTC,positive
46923.0,AGTC Reports Orphan Drug Designation in the European Union for Gene Therapy to Treat Achromatopsia,2015-10-22 07:01:00-04:00,AGTC,positive
46924.0,AGTC Announces Data Evaluating the Natural History of Patients With X-Linked Retinoschisis at 48th Annual Retina Society Meeting,2015-10-07 07:06:00-04:00,AGTC,positive
46925.0,AGTC Reports Publication of Data Supporting Further Investigation of Novel Potential Gene Therapy for Treating X-Linked Retinoschisis (XLRS) in Clinical Studies,2015-09-30 16:16:00-04:00,AGTC,positive
46926.0,Applied Genetic Technologies Reports Quarter Ended EPS $(0.48) vs. Est. $(0.41),2015-09-10 16:12:00-04:00,AGTC,neutral
46927.0,"AGTC Reports XLRS Patient Enrollment Mileston Achieved In Biogen Collaboration, Will Receive $5M Payment",2015-08-27 07:20:00-04:00,AGTC,neutral
46928.0,13G Filing from Biogen on Applied Genetic Technologies Shows New 8.1% Stake,2015-08-20 16:16:00-04:00,AGTC,neutral
46929.0,Morning Market Gainers,2015-08-20 09:44:00-04:00,AGTC,neutral
46930.0,Benzinga's Top #PreMarket Gainers,2015-08-20 08:18:00-04:00,AGTC,positive
46931.0,AGTC Release Confirms Strategic Collaboration With Biogen Effective and Biogen Equity Investment Closed,2015-08-19 16:09:00-04:00,AGTC,positive
46932.0,Benzinga's Top Initiations,2015-07-22 09:55:00-04:00,AGTC,positive
46933.0,"Chardan Capital Initiates Coverage on Applied Genetic Tech at Buy, Announces $25.00 PT",2015-07-22 08:10:00-04:00,AGTC,neutral
46934.0,Benzinga's Volume Movers,2015-07-06 10:35:00-04:00,AGTC,neutral
46935.0,"Biogen Collaboration With Applied Genetic Is 'Interesting,' But Morgan Stanley Will Wait For More Data",2015-07-06 07:51:00-04:00,AGTC,neutral
46936.0,Mid-Afternoon Market Update: International Speedway Slips On Weak Results; Applied Genetic Technologies Shares Spike Higher,2015-07-02 15:02:00-04:00,AGTC,negative
46937.0,"UPDATE: Wedbush's Nierengarten Views AGTC, Biogen Deal as 'validation of AGTC's patent-protected manufacturing technology and treatment focus on monogenic disorders'",2015-07-02 12:59:00-04:00,AGTC,neutral
46938.0,"Wedbush's David Nierengarten on Applied Genetics Following Biogen Deal: Calls Partnership an 'Operational Inflection Point' for AGTC; Outperform Rating, $36 Price Target Reiterated",2015-07-02 12:58:00-04:00,AGTC,neutral
46939.0,Mid-Day Market Update: US Stocks Down; Xoom Shares Jump On Acquisition News,2015-07-02 12:48:00-04:00,AGTC,positive
46940.0,"Thursday's Mid-Day Movers: Real Good Solar, Xoom, ConforMIS, Health Net And More",2015-07-02 12:02:00-04:00,AGTC,positive
46941.0,Mid-Morning Market Update: Markets Edge Higher; Centene To Acquire Health Net For $6.3B,2015-07-02 11:05:00-04:00,AGTC,neutral
46942.0,Benzinga's Volume Movers,2015-07-02 10:21:00-04:00,AGTC,neutral
46943.0,Morning Market Gainers,2015-07-02 09:40:00-04:00,AGTC,neutral
46944.0,Benzinga's Top #PreMarket Gainers,2015-07-02 08:16:00-04:00,AGTC,positive
46945.0,Applied Genetics Technologies Shares Trading Up 22% Following Resumption,2015-07-02 07:43:00-04:00,AGTC,positive
46946.0,Applied Genetic Technologies Shares to Resume Trading at 7:30AM ET,2015-07-02 07:06:00-04:00,AGTC,positive
46947.0,UPDATE: Biogen's Upfront Payment to AGTC Includes $30M Equity Investing in AGTC,2015-07-02 07:02:00-04:00,AGTC,neutral
46948.0,"UPDATE: AGTC Will Receive ~$124M Upfront Payment, Includes Potential for Future Milestone Payments",2015-07-02 07:02:00-04:00,AGTC,neutral
46949.0,"Biogen, AGTC Announce Entering of Collab Related to Development of Gene Therapies in Ophthalmology",2015-07-02 07:00:00-04:00,AGTC,neutral
46950.0,Applied Genetic Technologies Shares Halted News Pending,2015-07-02 06:55:00-04:00,AGTC,positive
46951.0,Applied Genetics Technologies Names Mark Shearman Chief Scientific Officer,2015-06-01 07:03:00-04:00,AGTC,neutral
46952.0,AGTC Earlier Reported New Data Showing Support for Novel Gene-Based Therapies for Rare Inherited Retinal Diseases,2015-05-18 07:15:00-04:00,AGTC,positive
46953.0,S-3 from Applied Genetic Technologies Shows Registration for $125M Common Shelf Offering,2015-05-11 16:59:00-04:00,AGTC,neutral
46954.0,Novel Gene-Based Therapy for Achromatopsia Developed by AGTC Demonstrates Functional Rescue of Cone Cells,2015-05-05 04:37:00-04:00,AGTC,positive
46955.0,"AGTC, 4D Molecular Therapeutics Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development",2015-04-20 07:07:00-04:00,AGTC,positive
46956.0,US Stock Futures Tumble Ahead Of Wholesale Inventories Data,2015-03-10 07:08:00-04:00,AGTC,neutral
46957.0,AGTC Files IND Application for Treatment of X-Linked Retinoschisis,2015-03-10 07:01:00-04:00,AGTC,neutral
46958.0,AGTC Appoints Stephen Potter Chief Business Officer,2015-01-29 07:01:00-05:00,AGTC,neutral
46959.0,"Stifel Nicolaus Maintains Buy on Applied Genetic, Raises PT to $31.00",2014-11-13 07:32:00-05:00,AGTC,neutral
46960.0,Applied Genetic Reports Q1 EPS of $(0.34) Which May Not Compare $(0.29) Est; Revenue of $705.0K Which May Not Compare $270.0K Est,2014-11-12 16:10:00-05:00,AGTC,neutral
46961.0,UPDATE: Stifel Initiates Coverage On Applied Genetic Technologies Corporation On Good Market Position,2014-10-03 09:14:00-04:00,AGTC,positive
46962.0,"Stifel Nicolaus Initiates Coverage on Applied Genetic at Buy, Announces $29.00 PT",2014-10-03 08:57:00-04:00,AGTC,neutral
46963.0,"CORRECTION: Wunderlich Initiates Coverage on Applied Genetic at Buy, Announces $29.00 PT",2014-10-03 06:53:00-04:00,AGTC,neutral
46964.0,"Stifel Nicolaus Initiates Coverage on Applied Genetic at Buy, Announces $29.00 PT",2014-10-03 06:35:00-04:00,AGTC,neutral
46965.0,"Applied Genetic Technologies Reports Q4 Loss $0.32/Share vs Loss of $13.10/Share in Same Qtr. Last Year, Sales $124K vs $377K YoY",2014-09-26 16:03:00-04:00,AGTC,negative
46966.0,Applied Genetic Technologies Prices 2M Share Offering @$15.00/Share,2014-07-24 19:07:00-04:00,AGTC,positive
46967.0,Applied Genetic Reports Q3 EPS of $(25.45) Which May Not Compare $(0.37) Est; Revenue of $232.0K Which May Not Compare $150.0K Est,2014-05-14 16:42:00-04:00,AGTC,neutral
46968.0,Benzinga's Top Initiations,2014-04-21 08:49:00-04:00,AGTC,positive
46969.0,"BMO Capital Initiates Coverage on Applied Genetic at Outperform, Announces $21.00 PT",2014-04-21 07:19:00-04:00,AGTC,neutral
46970.0,"AGTC Announces Closing of Initial Public Offering, Expects $51.8M in Proceeds",2014-04-03 16:02:00-04:00,AGTC,neutral
46971.0," Glaxosmithkline Buys 103,762 Shares of Applied Genetic Technologies at $12.00 -Form 4",2014-04-02 12:44:00-04:00,AGTC,positive
46972.0,"IPO March Madness Continues! TNET, AGTC, SQBK Open on March 27",2014-03-27 17:37:00-04:00,AGTC,negative
46973.0,"Applied Genetics Opens at $12.75/Share, Priced at $12",2014-03-27 10:25:00-04:00,AGTC,neutral
46975.0,Applied Genetic Technologies Prices 4.2M Share IPO at $12.00/Share,2014-03-26 19:00:00-04:00,AGTC,positive
46976.0,'Candy Crush' Maker King Digital Entertainment Gets Crushed: IPO Review For March 26,2014-03-26 16:39:00-04:00,AGTC,negative
46977.0,"Applied Genetic Files $70M IPO, Will List on NASDAQ Under 'AGTC'",2014-01-10 16:59:00-05:00,AGTC,neutral
